Michelle Haber is a world-renowned authority in the field of childhood cancer research and a key leader of the Australian biomedical research community. She has made fundamental discoveries in the area of drug resistance in neuroblastoma, and has pioneered molecular diagnostics and precision medicine for Australian children with leukaemia and other high-risk cancers. Haber's work has had a major impact on the global research community, and been translated into new therapeutics and changed models of care for Australian child cancer sufferers.